Neuphoria Therapeutics (NEUP) Operating Income (2023 - 2026)
Neuphoria Therapeutics (NEUP) reported Operating Income of -$1.2 million for Q1 2026, down 110.12% year-over-year from $12.0 million in Q1 2025, and up 70.16% on a QoQ basis from -$4.1 million in Q4 2025.
Neuphoria Therapeutics (NEUP) has 4 years of Operating Income data on file, last reported at -$1.2 million in Q1 2026.
- Quarterly Operating Income fell 110.12% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.8 million (down 226.73% YoY) and the FY2025 annual result came in at -$1.1 million, up 71.01% from the prior year.
- Operating Income rose to -$1.2 million in Q1 2026 per NEUP's latest filing, from -$4.1 million in the prior quarter.
- Across five years, Operating Income topped out at $12.0 million in Q1 2025 and bottomed at -$5.8 million in Q2 2025.
- The 4-year median for Operating Income is -$3.7 million (2024), against an average of -$1.4 million.
- Peak annual rise in Operating Income reached 600.29% in 2025, while the deepest fall reached 168.49% in 2025.
- Tracing NEUP's Operating Income over 4 years: stood at -$4.6 million in 2023, then climbed by 18.66% to -$3.7 million in 2024, then decreased by 9.65% to -$4.1 million in 2025, then surged by 70.16% to -$1.2 million in 2026.
- Per Business Quant, the three latest NEUP Operating Income figures stand at -$1.2 million (Q1 2026), -$4.1 million (Q4 2025), and -$5.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | -1.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.21 Mn |
| Dec 31, 2025 | -4.06 Mn |
| Sep 30, 2025 | -5.65 Mn |
| Jun 30, 2025 | -4.88 Mn |
| Mar 31, 2025 | 11.98 Mn |
| Dec 31, 2024 | -3.70 Mn |
| Sep 30, 2024 | -3.57 Mn |
| Jun 30, 2024 | 8.52 Mn |
| Mar 31, 2024 | -2.39 Mn |
| Dec 31, 2023 | -4.55 Mn |
| Sep 30, 2023 | -5.47 Mn |